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1. Introduction
The term myasthenia gravis (MG) is derived from the Greek terms my, asthenia, 
and gravis, which mean muscle, weakness, and severe, respectively. Myasthenia 
gravis is a rare potentially fatal chronic autoimmune disorder, in which circulating 
autoantibodies directed against components of the neuromuscular junction (NMJ) 
of skeletal muscles, most commonly nicotinic acetylcholine receptor (AChR) 
and associated protein in the postsynaptic membrane, will block neuromuscular 
transmission resulting in muscle weakness [1]. The muscle weakness is typically 
worsened with continued activity, improves on rest, and is of variable severity 
ranging from mild ocular muscle weakness to severe generalized muscle weakness 
involving the respiratory muscle with impending respiratory failure.
2. Historical perspective
The first reported case of MG could be traced to the Native American Chief 
Opechancanough, who died in 1664. “The excessive fatigue he encountered 
wrecked his constitution; his flesh became macerated; his sinews lost their tone 
and elasticity; and his eyelids were so heavy that he could not see unless they were 
lifted up by his attendants …he was unable to walk; but his spirit rising above the 
ruins of his body directed from the litter on which he was carried by his Indians” 
[2, 3]. An English physician, Thomas Willis, in 1672 described a patient with a 
typical myasthenic fatigable weakness of limb and bulbar muscles [4]. The late 
1800s certify the publishing first modern description of patients with myasthenia 
symptoms when Wilks in 1877 described bulbar and peripheral muscular weak-
ness without any pathology of the central nervous system [5]. A great advance 
in understanding MG and its management were achieved in 1934 by Walker who 
found the symptoms of MG were similar to curare poisoning and was treated 
with a cholinesterase inhibitor, physostigmine. Walker showed that the symptoms 
of MG promptly improved by the administration of physostigmine [6]. In 1937, 
Blalock established the removal of thymus as a treatment for MG [4]. Simpson and 
Nastuck suggested the autoimmune etiology of MG in 1959–1960 [7, 8] depend-
ing on several observations. In the 1970s, prednisolone, azathioprine, and, later, 
plasma exchange were established as treatments for MG [2].
3. Epidemiology
The worldwide prevalence of MG is 100–200 per million population [9], 
affecting more than 700,000 people all over the world [10]. The prevalence rate 
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has increased since the 1950s due to improved diagnostic precision and decreased 
mortality rate. It occurs in both genders, in all ages from different ethnic 
groups with variable prevalence and annual incidence rate from one country to 
another. Female-to-male ratio for incidence is 3:2 in people below the age of 30 
and 1:1.5 in people more than 50 years of age. Life-threatening MG crises occur 
approximately in 15–20% of patients, typically within the first 2 years of diag-
nosis [11]. Previously, MG crises were associated with 50–80% mortality rate. 
Currently, the overall inpatient mortality rate of MG is 2.2%, being higher in 
crises (4.47%). Older age and respiratory failure were the predictors for death in 
MG crises [12].
4. Etiology
Myasthenia gravis is an autoimmune disease mediated by organ-specific anti-
body. These antibodies are present at neuromuscular junction (NMJ) and directed 
against nicotinic acetylcholine receptor (AChR) on the postsynaptic muscle 
membrane in 80–90% of patients. In 3–7%, the autoantibodies are directed 
against another NMJ protein, muscle-specific tyrosine kinase (MuSK). Using 
cell-based assay may increase the rate of detection of autoantibodies in patients 
with negative result by standard binding and modulating technique [13]. Patients 
with negative antibodies against AChR and MuSK might show positive antibodies 
against low-density lipoprotein receptor-related protein (LRP4) [14]. Other types 
of antibodies might be detected in patients with MG like agrin antibodies and 
antibodies to collagen Q and cortactin. These antibodies are of debatable clinical 
importance [15]. The reason why some patients develop these autoantibodies 
remains unclear. Genetic predisposition linked to human leukocyte antigen 
complex, single nuclear polymorphism, association with thymic hyperplasia or 
thymoma and abnormalities in the number and function of regulatory T and B 
cells are probably playing a role in the etiology of MG [16–19]. Risk factors for 
developing MG include positive personal or family history of autoimmune disease 
like rheumatoid arthritis, HLA-B8, DR3, and women being less than 40 and men 
more than 60 years of age.
5. Pathophysiology
Normally, Ach is released in a discrete package from the motor nerve termi-
nal at the neuromuscular junction. These Ach quanta diffuse across the synaptic 
cleft and bind to receptors on the folded muscle end plate membrane (Figure 1). 
Motor nerve stimulation will release many Ach quanta causing depolarization 
of muscle end plate membrane resulting in muscle contraction. In MG, Ach was 
released normally but its effect on the postsynaptic membrane reduced. The 
autoantibody against AChRs will result in the destruction of postsynaptic mem-
brane and reduction in the number of available Ach receptors on the muscle end 
plate membrane (binding site for Ach), which in turn will lead to an inconsis-
tent generation of muscular action potentials manifesting as muscle weakness 
(Figures 2 and 3). The process of destruction of the postsynaptic membrane 
is dependent on complement activation. In patients without antibodies against 
AChRs, a muscle-specific tyrosine kinase (MuSK), an agrin-dependent pro-
tein on muscle membrane, has been found to be the antigenic target. These 
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Figure 1. 
Mechanism of muscle activation. Adopted from the free domain: http://pathologicallyspeaking.blogspot.
com/2015/07/speech-therapy-treatment-for-myasthenia.htm.
Figure 2. 
Mechanisms of inhibition of neurotransmission by anti-AChR antibodies. Adopted from the free domain: 
https://www.jci.org/articles/view/29894/figure/2.
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autoantibodies are T-cell dependent and there is interesting differential involve-
ment of muscle groups, especially the extraocular muscles [20].
6. Clinical presentation
Fatigable weakness, involving specific susceptible groups of muscles, is the 
clinical hallmark of MG. This weakness usually fluctuates from hour to hour, day to 
day, worsens with activity, and improves on rest. The susceptible groups of muscles 
include ocular, bulbar, facial, limb muscle, axial muscle, and respiratory muscle. 
Clinical features resulting from the involvement of the susceptible group of muscle 
are summarized in Table 1 [21].
The most common initial presenting feature of MG is ocular muscle involve-
ment presenting as fluctuating ptosis and/or diplopia, with or without general-
ized weakness, in about 85% of cases [22]. The absence of ocular involvement 
makes the diagnosis difficult. In 50–60% of patients with isolated ocular involve-
ment, progression to generalized weakness occurs within 2 years of the onset. The 
Figure 3. 
Pathogenesis of MG. Adopted from the free domain: https://www.nejm.org/doi/full/10.1056/NEJMra1602678.
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second most common presenting feature is bulbar muscle involvement manifest-
ing as dysphagia, dysarthria, dysphonia, or difficulties in chewing, occurring 
in about 15% of cases [23]. A life-threatening respiratory muscle involvement, 
requiring immediate therapeutic action might occur on rare occasions. Patients 
with MG usually experience a variable course with intermittent worsening of 
symptoms precipitated by viral infection, surgery, warm weather, immunization, 
emotional stress, pregnancy, chronic diseases, or medications. Progression to 
maximum severity usually occurs with the first 2 years of onset and spontaneous 
long-term remission might occur in up to 10–20% of patients [22]. About 10–20% 
of infants born to mothers with symptomatic or asymptomatic MG present soon 
after birth with transient neonatal MG. It occurs as a result of transplacental pas-
sage of antibodies against NMJ receptors. The most common presenting features 
are hypotonia and poor feeding that resolve usually within the first months after 
birth [24].
7. Clinical classifications
Myasthenia gravis is classified clinically into five classes and several sub-
classes according to MG foundation of American clinical classification, see  
Table 2 [25].
Group of muscle Clinical features
Ocular muscle Fluctuating ptosis and/or diplopia
Bulbar muscle Dysarthria, painless dysphagia, dysphonia, and masticatory weakness
Facial muscle Facial weakness, inability to close eye firmly, drooling of saliva
Axial muscular Flexion or extension of the neck
Limb muscle Weakness involving the arms more than legs
Respiratory muscle Labor breathing, orthopnea, dyspnea, and respiratory failure
Table 1. 
Signs and symptoms of MG.
Class Clinical description
Class 1 Any eye muscle weakness, possible ptosis, all other muscles’ strength is normal
Class 2
2a
2b
Mild weakness of other muscles; may have eye muscle weakness of any severity
Predominantly limb or axial muscles weakness or both
Predominantly oropharyngeal or respiratory muscle weakness or both
Class 3
3a
3b
Moderate weakness of other muscles; may have eye muscle weakness of any severity
Predominantly limb or axial muscle weakness or both
Predominantly oropharyngeal or respiratory muscle weakness or both
Class 4
4a
4b
Severe weakness of other muscles; may have eye muscle weakness of any severity
Predominantly limb or axial muscle weakness or both
Predominantly oropharyngeal or respiratory muscle weakness or both; use of feeding tube 
without intubation
Class 5 Intubation needed to maintain airway
Table 2. 
Clinical classification of MG.
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8. Diagnosis
The diagnosis of MG might be difficult and easily missed, because of the rarity 
of the condition and hence unfamiliarity to physicians. Furthermore, fluctuations 
of muscle weakness may add to the perplexing presentation. Once MG is suspected, 
the following test can be requested:
8.1 Serological tests
Anti-AchR has about 100% specificity, 85% sensitivity in patients with general-
ized MG, and 50% sensitivity in pure ocular variety [26]. False positive results may 
occur in patients with thymoma without MG, small cell lung cancer, rheumatoid 
arthritis treated with penicillamine, and rarely in people over 70 years of age. 
Other serological tests include anti-MuSK antibody (positive in 50% of myasthenic 
patients with negative anti-AchR), anti-agrin antibody, anti-lipoprotein-related 
protein 4 (LRP4) antibody, antistriational antibody (present in all myasthenic 
patients with thymoma), and anti-cortactin antibody.
8.2 Neurophysiological studies
These studies are commonly used to detect defects in neuromuscular transmis-
sion in patients with MG. Repetitive nerve stimulation and single-fiber electro-
myography are the most commonly used tests. Repetitive nerve stimulation can 
detect 75 and <50% of generalized and ocular MG patients, respectively. On the 
other hand, single-fiber electromyography can detect defects in neuromuscular 
transmission in 95–99% of myasthenic patients and a negative result can exclude 
the diagnosis [27].
8.3 Radiological studies
Chest X ray, CT scan, and MRI might be recommended to  evaluate patients with 
anterior mediastinal mass and suspected thymoma, and also to exclude brain and 
orbit mass lesion inducing cranial nerve palsies in ocular MG.
8.4 Pharmacological tests
In MG, the number of AChRs at the NMJ is low due to inhibition by the auto-
antibody. The result is decrease in the number of interaction between Ach (release 
from motor nerve terminals) and its receptors on postsynaptic muscle membrane of 
NMJ. The Ach is metabolized by Ach esterase (AChE) enzyme. Therefore, inhibition 
of this enzyme will increase the Ach concentration at the NMJ and hence improve 
the chance of interaction between the Ach and its receptors. Edrophonium test is 
based on the clinical improvement of muscle weakness in myasthenic patients after 
intravenous administration of short-acting Ach esterase inhibitor, Edrophonium 
(Tensilon). Double blinding of both the patient and the examiner increases the 
validity of the test [28].
8.5 Ice pack test
This debatable test uses the fact that cooling might improve neuromuscular 
transmission. It is mainly used by ophthalmologists to assess improvement in ptosis 
and diplopia in myasthenic patients [29].
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9. Treatment
The severity of symptoms in patients with MG will determine the strategy of the 
treatment using the many therapeutic options available. According to MG founda-
tion of American clinical classification (Table 2), MG can be divided into three 
categories: mild (classes 1 and 2), moderate (class 3), and severe (classes 4 and 5). 
The available therapeutic options include:
9.1 Pharmacologic therapy
The cornerstone for the treatment of MG is the administration of reversible 
cholinesterase (AChE) inhibitor, pyridostigmine, which is more effective in patients 
with generalized and ocular MG and less effective in patients with positive anti-
MuSK antibody. In those patients with poor response to pyridostigmine, steroid and 
immunosuppressive agents should be considered [30–32].
9.2 Immunosuppressive agent
All types of MG respond to corticosteroid (prednisone and prednisolone) in 
terms of improvement of muscle strength. Furthermore, corticosteroid may pre-
vent progression of the disorder from ocular to generalized MG [30, 33]. Patients 
who do not respond to corticosteroid or who cannot tolerate it are candidates for 
immunosuppressive agents using azathioprine (they are first-line agents and can be 
used with corticosteroid), cyclosporine, methotrexate, mycophenolate mofetil, or 
tacrolimus [32]. Recently, promising results are shown by two monoclonal antibod-
ies, rituximab and eculizumab. The use of rituximab in refractory MG may show 
clinical improvement and reduction for the need of corticosteroid and therapeutic 
plasma exchange [34].
9.3 Therapeutic plasma exchange (TPE)
It is the procedure by which the patient’s plasma is removed and replaced by fresh 
plasma or albumin. This will lead to the removal of autoantibody against AChRs, lead-
ing to short-term improvement of NMJ transmission and hence muscular strength. It 
is useful as an acute treatment in patients with severe generalized MG, refractory MG, 
myasthenia crises, and as maintenance therapy in patients with juvenile MG [35].
9.4 Intravenous immunoglobulin (IVIG)
The mechanism of action of IVIG is complex and may involve inhibition of cyto-
kines and complement deposition, competition with autoantibodies, interference with 
binding of Fc receptor on macrophages and immunoglobulin receptor on B cells, and 
interference with antigen recognition by sensitized T cells [36]. It is used as an acute 
treatment in patients with severe generalized MG and MuSK-MG, as a maintenance 
therapy in patients with refractory and juvenile MG, and in myasthenia crises [1].
9.5 Thymectomy
Myasthenic patients commonly have thymic abnormalities. Patients with gener-
alized MG have thymic hyperplasia in 85% and thymoma in 10–15% of cases. Those 
patients are usually anti-AChR antibody positive. Thymectomy is indicated for all 
patients with thymoma and for patients aged 10–55 years who have generalized MG 
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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but without thymoma. In fact, thymectomy is proposed as first – line therapy in most 
patients with generalized MG. Thymectomy not indicated in patients with antibod-
ies to MuSK, LRP4, or agrin antibodies because the thymic pathology is different 
from the more common type of MG characterized by seropositivity to AChR, and 
also it is not indicated in patients with ocular MG during the first 2 years after 
diagnosis because the possibility of spontaneous remission [2].
10. Prognosis
With the recent advances in the management of MG in both supportive intensive 
care and specific therapeutic options, most patients enjoy normal or near normal life 
span. The mortality rate is about 3–4% and the risk factors for death include a short 
history of a progressive disease, age more than 40 years, and thymoma. Morbidity 
in MG results from intermittent muscle weakness, which may result in aspiration 
pneumonia, difficult breathing, and even respiratory failure requiring ventilator 
assistance and in possible side effects of medications used in the treatment.
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